Genetic Technologies Limited (GNTLF) 6-K Current report (foreign)

Exhibit 99.1

Appendix 3Y

Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: Genetic Technologies Limited

ABN: 17 009 212 328

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Peter Irwin Rubenstein
Date of last notice	27 December 2023

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Irwin Biotech Nominees Pty Ltd <BIO A/C>
Date of change	From 29 February to 6 March 2024.
No. of securities held prior to change	Irwin Biotech Nominees Pty Ltd <BIO A/C> 870,494 Ordinary shares Irwin Biotech Nominees Pty Ltd 20,000 Ordinary shares 865,827 Ordinary shares (represented by 28,861 American Depositary Receipts) RIP Opportunities Pty Ltd 75,000 Ordinary shares (represented by 2,500 American Depositary Receipts) RIP Opportunities Pty Ltd <PIR Super Fund A/C> 1,250,000 Ordinary shares

+ See chapter 19 for defined terms.
Appendix 3Y Page 1	01/01/2011

Appendix 3Y

Change of Director’s Interest Notice

Class	Ordinary shares
Number acquired	617,209
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$80,315.18, an average of approximately 13 cents per ordinary share.
No. of securities held after change	Irwin Biotech Nominees Pty Ltd <BIO A/C> 1,487,703 Ordinary shares Irwin Biotech Nominees Pty Ltd 20,000 Ordinary shares 865,827 Ordinary shares (represented by 28,861 American Depositary Receipts) RIP Opportunities Pty Ltd 75,000 Ordinary shares (represented by 2,500 American Depositary Receipts) RIP Opportunities Pty Ltd <PIR Super Fund A/C> 1,250,000 Ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On Market Trades

+ See chapter 19 for defined terms.
Appendix 3Y Page 2	01/01/2011

Appendix 3Y

Change of Director’s Interest Notice

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.
Appendix 3Y Page 3	01/01/2011